These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 3688278)

  • 21. High doses of fluphenazine enanthate in schizophrenia. A controlled study.
    Dencker SJ; Johansson R; Lundin L; Malm U
    Acta Psychiatr Scand; 1978 May; 57(5):405-14. PubMed ID: 354329
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect size of symptom status in withdrawal of typical antipsychotics and subsequent clozapine treatment in patients with treatment-resistant schizophrenia.
    Pickar D; Bartko JJ
    Am J Psychiatry; 2003 Jun; 160(6):1133-8. PubMed ID: 12777272
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical and quantitative EEG changes at different dosage levels of fluphenazine treatment.
    Itil TM; Saletu B; Hsu W; Kiremitci N; Keskiner A
    Acta Psychiatr Scand; 1971; 47(4):440-51. PubMed ID: 4947806
    [No Abstract]   [Full Text] [Related]  

  • 24. Effect of pimozide on positive and negative symptoms in schizophrenic patients: are negative symptoms state dependent?
    van Kammen DP; Hommer DW; Malas KL
    Neuropsychobiology; 1987; 18(3):113-7. PubMed ID: 3453426
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Positive and negative symptoms, depression and social disability in chronic schizophrenia: a comparative trial of bromperidol and fluphenazine decanoates.
    McLaren S; Cookson JC; Silverstone T
    Int Clin Psychopharmacol; 1992 Nov; 7(2):67-72. PubMed ID: 1487623
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Diazepam treatment of early signs of exacerbation in schizophrenia.
    Carpenter WT; Buchanan RW; Kirkpatrick B; Breier AF
    Am J Psychiatry; 1999 Feb; 156(2):299-303. PubMed ID: 9989567
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Changes in plasma homovanillic acid concentrations in schizophrenic patients following neuroleptic discontinuation.
    Davidson M; Kahn RS; Powchik P; Warne P; Losonczy MF; Kaminsky R; Apter S; Jaff S; Davis KL
    Arch Gen Psychiatry; 1991 Jan; 48(1):73-6. PubMed ID: 1670618
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Improvement of schizophrenic patients with primary negative symptoms treated with amisulpride. Amisulpride Study Group.
    Danion JM; Rein W; Fleurot O
    Am J Psychiatry; 1999 Apr; 156(4):610-6. PubMed ID: 10200742
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Changes in psychopathology and dyskinesia after neuroleptic withdrawal in a double-blind design.
    Dixon L; Thaker G; Conley R; Ross D; Cascella N; Tamminga C
    Schizophr Res; 1993 Oct; 10(3):267-71. PubMed ID: 8260445
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effects of ceruletide in schizophrenia.
    Hommer DW; Pickar D; Roy A; Ninan P; Boronow J; Paul SM
    Arch Gen Psychiatry; 1984 Jun; 41(6):617-9. PubMed ID: 6329121
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Idazoxan, an alpha 2 antagonist, augments fluphenazine in schizophrenic patients: a pilot study.
    Litman RE; Hong WW; Weissman EM; Su TP; Potter WZ; Pickar D
    J Clin Psychopharmacol; 1993 Aug; 13(4):264-7. PubMed ID: 8104200
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The positive and negative symptoms of schizophrenia: patterns of response to depot neuroleptic treatment.
    Martyns-Yellowe IS
    West Afr J Med; 1994; 13(4):200-3. PubMed ID: 7756183
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adjunctive fluoxetine in the treatment of negative symptoms in chronic schizophrenic patients.
    Spina E; De Domenico P; Ruello C; Longobardo N; Gitto C; Ancione M; Di Rosa AE; Caputi AP
    Int Clin Psychopharmacol; 1994; 9(4):281-5. PubMed ID: 7868850
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ritanserin, a selective 5-HT2/1C antagonist, and negative symptoms in schizophrenia. A placebo-controlled double-blind trial.
    Duinkerke SJ; Botter PA; Jansen AA; van Dongen PA; van Haaften AJ; Boom AJ; van Laarhoven JH; Busard HL
    Br J Psychiatry; 1993 Oct; 163():451-5. PubMed ID: 7902766
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Modification of schizophrenia by intensive neuroleptic therapy and the course of the disease after withdrawal of neuroleptic drugs].
    Steiner S
    Psychiatr Clin (Basel); 1980; 13(3-4):165-78. PubMed ID: 7244281
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Further studies with fluphenazine enanthate: II. Relapse rate in patients deprived of medication.
    Ravaris CL; Weaver LA; Brooks GW
    Am J Psychiatry; 1967 Aug; 124(2):248-9. PubMed ID: 4952779
    [No Abstract]   [Full Text] [Related]  

  • 37. Phenothiazine-induced decompensation.
    Van Putten T; Mutalipassi LR; Malkin MD
    Arch Gen Psychiatry; 1974 Jan; 30(1):102-5. PubMed ID: 4587065
    [No Abstract]   [Full Text] [Related]  

  • 38. Fluphenazine plasma levels, dosage, efficacy, and side effects.
    Levinson DF; Simpson GM; Lo ES; Cooper TB; Singh H; Yadalam K; Stephanos MJ
    Am J Psychiatry; 1995 May; 152(5):765-71. PubMed ID: 7726317
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A placebo-controlled trial of fluoxetine added to neuroleptic in patients with schizophrenia.
    Goff DC; Midha KK; Sarid-Segal O; Hubbard JW; Amico E
    Psychopharmacology (Berl); 1995 Feb; 117(4):417-23. PubMed ID: 7604142
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Computerized EEG: predictor of outcome in schizophrenia.
    Itil TM; Marasa J; Saletu B; Davis S; Mucciardi AN
    J Nerv Ment Dis; 1975 Mar; 160(3):118-203. PubMed ID: 1090708
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.